Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03157830 · ClinicalTrials.gov registry record
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by Providence Health & Services.
- Completed
- Registry status
- 43
- Enrollment target
- 5
- Study locations
NCT03157830: Completed study of Relapsing Remitting Multiple Sclerosis, sponsored by Providence Health & Services.
NCT03157830 is a study of Relapsing Remitting Multiple Sclerosis that has completed, run by Providence Health & Services. The registered enrollment target is 43 participants, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (79% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03157830, a study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.
Primary Outcome
The proportion of relapse-free patients at month 12 after switching from natalizumab to ocrelizumab.
Conditions Studied
Study Locations (5)
Washington
- Kadlec Neuroscience Center - Richland
- Multiple Sclerosis Center, Swedish Neuroscience Institute - Seattle
- Providence Multiple Sclerosis Center - Spokane
New Jersey
- RWJBarnabas Health - Livingston
Oregon
- Providence MS Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2022-06-06 |
What the finished NCT03157830 record still lists
NCT03157830 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT03157830 lists 5 locations in 3 states (Washington, New Jersey, Oregon).
Frequently Asked Questions
What is clinical trial NCT03157830 about?
NCT03157830 is a clinical study titled "Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab". The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.
What is the current status of trial NCT03157830?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2017-06-01. Estimated completion is 2022-06-06.
What conditions does trial NCT03157830 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
Who is sponsoring clinical trial NCT03157830?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03157830 being conducted?
This trial has 5 study locations across New Jersey, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03157830's enrollment target sits among peer trials
43 19th of 25 higher than 7 of 25 other Relapsing Remitting Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI